

Radiation Oncology

Dept of Oncology
Waikato Hospital



Trans Tasman Radiation Oncology Group

Objectives of the Trans Tasman Radiation Oncology Group

The objectives of TROG are to:

- a) carry out investigator-driven research in oncology, primarily clinical trials involving radiation therapy designed to improve the outcomes of cancer treatment.
- b) foster optimal patient care through maintenance of standards and through independent clinical research including trials.
- c) foster regional cooperation between all radiation oncologists in the Australian and New Zealand regions, and specifically to promote coordinated multi-institution research endeavours.
- d) promote the highest ethical standard of care and research including quality assurance.

TROG Milestones

1989 – TROG established at Taupo, NZ meeting

1989 – First TROG trial activated

1990 – First TROG policy written leading to start of Policy & Procedure Manual (Red Book)

1990 – First TROG publication

1991 – First randomised trial (TROG 91.01 locally advanced H&N cancer)

1992 – First competitive funding obtained for a trial (TROG 91.01)


1994 – Part-time TROG Secretariat established at Newcastle Mater Hospital

- 2007 – TROG 07.01 study to become the first global breast cancer trial led by TROG following endorsement by the Breast International Group (BIG 3-07).
- 2008 – Appointment of NZ Project Officer
- 2008 – Appointment of TROG Trial Development Coordinator, Accountant, Policy & Procedures Officers, Communications Officer, Information Officer and QA Research Assistant
- 2008 – TROG approved as NHMRC Administering Institution for grant applications
- 2008 – TROG transfers business status to Company Limited by Guarantee
- 2008 – Nine (9) new trials approved for activation in one year
- 2008 – 8000 participants entered onto TROG trials to date


TROG at the Waikato

- 91.01 – Head & neck trial
- Open TROG trials – 7 (out of 10)
- No of patients entered into trials – 55
- 01.04 – Rectal cancer – 17
- 05.01 – POST – 7


05.01 – Skin POST




07.01 Breast DCIS




03.06 Prostate TOAD



08.03 Prostate RAVES



08.02 GBM > 65yrs



99.03 Follicular stage I/II NHL

Patient selection

Follicular lymphoma
Grades 1, 2 or 3a
Stage I or II

Stratification

Centre
Stage (I/II)
Age (<60/≥60)
Whether PET-staged¹

RANDOMISE


```
graph TD; A[RANDOMISE] --> B[Involved field RT 30-36 GY  
↓  
CVP + rituximab 1 x 6 cycles]; A --> C[Involved field RT 30-36 GY];
```

Involved field RT 30-36 GY

↓
CVP + rituximab¹ × 6 cycles

Involved field RT 30-36 GY

08.04 PORTEC-3



Recruitment

- No of patients entered into trials – 55!
- NZ project officer 2008
- TROG Research Forum Christchurch June 2009
 - Funding
 - Infrastructure
 - Communication
 - Research culture

